Compare EVGO & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGO | CADL |
|---|---|---|
| Founded | 2010 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.6M | 1.0B |
| IPO Year | 2020 | 2021 |
| Metric | EVGO | CADL |
|---|---|---|
| Price | $1.46 | $10.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $5.23 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 3.3M | 1.1M |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.39 | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,588,000.00 | $125,000.00 |
| Revenue This Year | $16.45 | N/A |
| Revenue Next Year | $29.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 145.74 | N/A |
| 52 Week Low | $1.23 | $4.35 |
| 52 Week High | $5.18 | $14.00 |
| Indicator | EVGO | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 41.77 |
| Support Level | $1.42 | $9.40 |
| Resistance Level | $1.52 | $11.36 |
| Average True Range (ATR) | 0.09 | 0.69 |
| MACD | 0.02 | -0.28 |
| Stochastic Oscillator | 79.31 | 27.99 |
EVgo Inc is an EV fast charging provider. The company deploys charging infrastructure by partnering with retailers, grocery stores, restaurants, gas stations, rideshare operators, and autonomous vehicle companies across the U.S., and serves the EV commercial segment by deploying fleet-charging solutions for light-duty EV fleets at depot locations, off-site charging hubs, or through its public network. It also owns PlugShare, a platform for EV drivers to locate public charging stations, plan trips and share charging experiences, which also provides charging location data licensing, infrastructure analysis, and EV driver research. It also derives revenue from the sale of regulatory credits earned from participation in LCFS programs and other carbon or emissions trading schemes in the U.S.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.